TrialBlood2014

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Nikoletta Lendvai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.